A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers by Yu, Kun et al.
A Precisely Regulated Gene Expression Cassette Potently
Modulates Metastasis and Survival in Multiple Solid
Cancers
Kun Yu
1,2, Kumaresan Ganesan
1, Lay Keng Tan
3, Mirtha Laban
2, Jeanie Wu
1, Xiao Dong Zhao
4, Hongmin
Li
2, Carol Ho Wing Leung
2, Yansong Zhu
1, Chia Lin Wei
4, Shing Chuan Hooi
2, Lance Miller
4, Patrick
Tan
1,3,4*
1National Cancer Centre, Singapore, Singapore, 2Department of Physiology, National University of Singapore, Singapore, Singapore, 3Duke–NUS Graduate Medical
School, Singapore, Singapore, 4Genome Institute of Singapore, Singapore, Singapore
Abstract
Successful tumor development and progression involves the complex interplay of both pro- and anti-oncogenic signaling
pathways. Genetic components balancing these opposing activities are likely to require tight regulation, because even
subtle alterations in their expression may disrupt this balance with major consequences for various cancer-associated
phenotypes. Here, we describe a cassette of cancer-specific genes exhibiting precise transcriptional control in solid tumors.
Mining a database of tumor gene expression profiles from six different tissues, we identified 48 genes exhibiting highly
restricted levels of gene expression variation in tumors (n=270) compared to nonmalignant tissues (n=71). Comprising
genes linked to multiple cancer-related pathways, the restricted expression of this ‘‘Poised Gene Cassette’’ (PGC) was
robustly validated across 11 independent cohorts of ,1,300 samples from multiple cancer types. In three separate
experimental models, subtle alterations in PGC expression were consistently associated with significant differences in
metastatic and invasive potential. We functionally confirmed this association in siRNA knockdown experiments of five PGC
genes (p53CSV, MAP3K11, MTCH2, CPSF6, and SKIP), which either directly enhanced the invasive capacities or inhibited the
proliferation of AGS cancer cells. In primary tumors, similar subtle alterations in PGC expression were also repeatedly
associated with clinical outcome in multiple cohorts. Taken collectively, these findings support the existence of a common
set of precisely controlled genes in solid tumors. Since inducing small activity changes in these genes may prove sufficient
to potently influence various tumor phenotypes such as metastasis, targeting such precisely regulated genes may represent
a promising avenue for novel anti-cancer therapies.
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Introduction
The accurate processing and integration of multiple external
signals is a common feature of biological networks in normal health
and complex disease. As illustrated by the examples of oxygen
handling [1], energy control [2], and ion homeostasis [3], such
accuracy frequently involves the precise coordination of multiple
cellular pathways, and mechanisms for regulating and balancing
opposing activities. In cancer networks, many similar requirements
for pathway balance are likewise found as successful tumorigenesis
requires the robust integration of both pro- and anti-oncogenic
pathways controlling cellular proliferation, apoptosis, motility,
adhesion and senescence [4,5]. The importance of balancing
opposing activities in cancer is illustrated by genes such as HEF1
(NEDD9), a metastasis-related gene [6] and HMMR, a gene involved
in centrosome formation (Pujana et al. 2007). Either repression or
overexpression of HEF1 can cause mitotic defects [7,8], indicating
that its activity in tumors requires tight regulation. Similarly, subtle
alterations of HMMR expression in normal mammary tissues may
promote breast tumorigenesis, underscoring the need to keep the
HMMR gene tightly regulated [9]. Such findings support the notion
that balancing the activity of positive and negative effectors is likely
to be a central requirement of many cancers.
At the systems-level, pathway balance is often facilitated through
the use of network structures [10] conveying robustness to random
fluctuations and errors [11–14]. However, the pivotal balancing role
played by certain genetic components may at least partially explain
why some networks also exhibit ultrasensitivity – a phenomena
where small changes in activity at specific components can suffice to
elicit qualitative changes in output [12,13]. Ultrasensitivity may
contribute to a network’s ability to rapidly respond to changing
environmental and genetic conditions [15,16]. Intriguingly, there is
emerging evidence that certain cancers can also display ultrasensi-
tivity. Some remarkable examples include the dramatic responses of
chronic lymphocytic leukemia cells to colchicines, occurring at
concentrations 10,000-fold lower than that required for similar
effects on normal lymphocytes [17,18], and the striking clinical
responses of certain solid tumors to targeted pathway inhibitors [19].
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could prove particularly appealing as drug targets, as even small
alterations might prove sufficient to induce potent effects on tumor
phenotypes such as tissue invasion and metastasis. However, our
current understanding of the role that ultrasensitivity plays in cancer
is still far from complete. Identifying additional genetic components
regulating pathwaybalanceintumorsmightthusimprove ourability
to target critical control nodes in cancer networks.
As a general strategy to identify ultrasensitive components in
tumors, we hypothesized that a) such components should be
precisely regulated and thus exhibit restricted levels of expression
variation in cancers; and b) subtle alterations in the expression
levels of these components should induce or be associated with
significant phenotypic changes. We then applied these criteria to
determine if such precisely-regulated genes might be inferred from
databases of tumor gene expression profiles. While several groups
have compared the expression profiles of multiple tumor and non-
malignant tissues [20,21], to our knowledge, no study to date has
systematically attempted to investigate the issue of precise gene
regulation in tumors. Employing a genome-wide computational
strategy, we identified and robustly validated a novel ‘‘Poised Gene
Cassette’’ (PGC) of genes undergoing precise regulation in a
microarray database of human tumors from diverse tissue types.
Furthermore, subtle alterations in PGC expression were associated
with significant and measurable alterations in important tumor
phenotypes such as experimental metastasis and patient survival.
Our results thus suggest the existence of a generalized homeostatic
mechanism in solid tumors for maintaining precise levels of PGC
transcription, which may be important for various cancer-
associated phenotypes, such as tissue invasion and metastasis.
Importantly, the approach described in this study is quite
generalizable and can be applied to other diseases.
Results
Defining a Cassette of Precisely Regulated Genes in
Multiple Solid Tumors
We hypothesized that genes precisely regulated in cancer should
exhibit a highly restricted level of gene expression variation across
a large database of individual tumor gene expression profiles. To
investigate this, we generated gene expression profiles for 270
primary tumors from six tissue types (breast, colon, liver, lung,
oesophageal and thyroid) using Affymetrix U133A Genechips. For
every gene, we computed gene expression coefficient of variances
(CV), where genes with small CVs are considered more tightly
regulated than genes with large CVs. We focused on the top 15%
most tightly-regulated genes in tumors, corresponding to an
empirical CV cut-off of 0.28. To identify genes whose tight
regulation was tumor-specific, we used a second database of 71
adjacent matched non-malignant tissues (‘‘control’’ tissues) to
eliminate from this 15% genes that were also tightly regulated in
non-malignant samples (CV.0.3). The use of an absolute CV
threshold is permissible, as the global distribution of expression
CVs between tumors and controls were highly similar (mean CVs
were 0.46 and 0.45 for tumors and controls) (Figure 1A). Using this
criterion, we identified a ‘‘Poised Gene Cassette’’ (PGC) of 48
genes exhibiting highly restricted levels of expression variation in
tumors (Figure 1B). The F-test, a statistical method for comparing
the variation of different data sets, confirmed that each of the 48
PGC genes was indeed associated with significantly decreased
expression variation in tumors relative to controls (one tailed F-
test, p=0.0001 to 4610
214). We also varied the CV threshold
between 0.26–0.3 (+/27%) and repeated the analysis. Similar
results were obtained (Table S1), indicating that the identification
of PGC is not dependent on a particular CV threshold.
The PGC Is not Biased Towards Probe Selection,
Normalization Technique, Expression Level, or Sample
Selection
We investigated whether the reduced expression variation of the
PGC might be due to technical features of the Affymetrix platform
or the composition of the initial training set. We considered the
possibility that the reduced variance of the PGC might be due to
an overabundance of ‘poor quality’ probes, which might be
expected to cross hybridize with multiple genes and hence
generate higher background signals [22]. However, an examina-
tion of a vendor provided list of questionable probes (i.e., with
‘_s_at’ and ‘_x_at’ suffixes), confirmed that the PGC was not
significantly enriched in poor quality probes (p=0.4). In addition,
a comparison of the PGC genes against an in-house curated list of
unreliable array probes based on sequence redundancy and repeat
mapping [23] confirmed that unreliable probes were not
overrepresented in the set of PGC genes (p=0.8).
To investigate the influence of normalization protocol on PGC
discovery, we re-processed the training set using a different
normalization method (RMA, [24,25]). In the RMA-normalized
data, we found that 90% of the original PGC genes still exhibited
decreased expression variation in tumors relative to controls (i.e.,
CV(control).CV(tumors)) (Figure 2A). Thus, the tumor-specific
restricted expression variation of the PGC does not appear to be
dependent upon a specific normalization technique.
The reduced variation of the PGC is also not due to an
overrepresentation of either high-expressing or low-expressing
genes. As shown in Figure 2B, the PGC genes were equally
distributed across a wide range of expression levels and not
confined to either low or highly expressing genes in tumors or
control tissues. Thus, the reduced expression variation of the PGC
in cancers is unlikely to be due to the PGC genes simply being
either highly expressed, rendering the PGC distinct from some
studies suggesting an inverse correlation between expression
variation and absolute expression levels [26]. Similarly, the PGC
is also not biased in lowly expressed genes, consistent with our
original selection criteria requiring these genes to be reliably
Author Summary
Successful carcinogenesis involves the integration of both
pro- and anti-oncogenic pathways. We postulated that
genes critical for balancing these opposing pathways are
likely to be precisely controlled in tumors, since even subtle
alterations in their activity might cause substantial alter-
ations in tumor growth and survival. Using a novel genomic
approach, we identified a 48-gene ‘‘Poised Gene Cassette’’
(PGC) showing tight regulation specifically in human
cancers but not in corresponding nonmalignant tissues.
We show, using a wide variety of in vitro and in vivo
approaches, that small alterations in PGC expression are
consistently associated with significant differences in
experimental metastasis and patient survival, and we
demonstrate a direct functional role for five PGC genes
(p53CSV, MAP3K11, MTCH2, CPSF6 and SKIP) in cancer
invasion. Our findings support the existence of a novel class
of ultrasensitive genes that may regulate various cancer-
associated phenotypes such as metastasis. Such precisely
controlled genes could represent appealing drug targets,
since even partial alterations in their activity should prove
sufficient to induce potent effects on tumors. Besides
cancer, our analytical approach is quite generalizable and
likely to be applicable to other disease conditions.
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important to note that the PGC genes do not exhibit significant
differences in their absolute mean expression levels between
cancers and normal tissues (Figures 1B and 2B), but instead only
differ in their levels of expression variation between cancers and
normal tissues. This observation, as well as others, also provides an
argument that the PGC genes are unlikely to represent tissue-
specific expression (see Discussion).
The discovery of the PGC is also not influenced by the
overrepresentation of breast tumors in our initial training set
(breast tumors comprised 68% of the training set). Specifically, we
removed all the breast tissues and repeated the PGC analysis.
Even without inclusion of breast tissues, 83% (40/48) of the PGC
genes still exhibited reduced variation in tumors compared to
controls. Of 47 genes exhibiting tumor-specific tight regulation in
the breast-excluded data (CV,0.28), 24 genes were part of the
original PGC, an overlap far beyond random chance (50%,
p=1.3E-11, hypergeometric test). Taken collectively, these results
suggest that the identification of the PGC, and its restricted
expression variation in cancers, is unlikely to be due to a technical
artifact or the inclusion of a specific cancer type.
A Cross-Validation Assay Confirms Specificity and
Robustness of the PGC Signature
To confirm that the restricted expression variation of the PGC
was specifically associated with malignancy, we determined the
frequencyatwhichamembergeneofthePGCcouldbere-identified
in a series of class-permutation tests. When the class labels of the
samples (i.e., tumor or control) were shuffled to generate a series of
1000 permuted sets, almost all the PGC genes (46/48, 96%) could
onlybere-identified inlessthan5%ofthe class-permutedsignatures,
consistent with the decreased expression variation of the PGC being
tightly associated with tumor samples.
We then evaluated the robustness of the PGC by repeated
random sampling (RSS), a stringent cross-validation strategy [27].
The original training set was randomly divided 1000 times into
two parts, generating a large series of distinct training/test set
combinations. For each of the 1000 derived RSS training sets, we
identified new PGC signatures (rPGC) and compared them to the
original PGC gene set. Following the guidelines of Michels et al
[27], 20 genes were repeatedly selected in more than half of the
1,000 new rPGC signatures. Of these 20 genes, 19 (95%) are
members of the original 48-gene PGC (Figure 2C) – the
observation that only one gene not part of the original PGC
signature was repeatedly selected in the RSS assay indicates that a
substantial proportion of the PGC signature (40%) is robust to
training set selection. To evaluate the transportability of the PGC
signatures, we then applied each of the 1000 rPGC signatures to
their cognate test sets. In anticipation that most independent test
sets are likely to contain either tumor or control samples but not
both, we considered the tumors and controls separately from one
another in this analysis. In each test set, we checked if the
population of tightly regulated genes, defined using the original
CVT threshold (0.28), contained a significant enrichment of rPGC
genes (see Methods). The rPGC signatures were significantly
enriched in the population of tightly regulated genes in 80% of the
tumor test sets (PGCRT, Figure 2D), and importantly were NOT
significantly enriched in 100% of the control test sets (PGCRN,
Figure 2D), indicating that the PGC is robust in recapitulating its
precise regulation in multiple tumor data sets, but not data sets of
non-malignant samples. Together, these results confirm the
specificity of the PGC for tumors.
Independent Validation of the PGC in Diverse Solid
Tumors
We then asked if the precision of PGC regulation in cancer
could be observed in independent data sets of diverse tumors. We
collected nine independent cancer cohorts, comprising in total
1105 cancer samples from .7 primary tissue types [28–32],
Figure 1. Gene expression variation in tumorand non-malignant
samples. A) Distribution of gene expression variation (CV) in tissue
samples. Equal numbers of tumor and control samples (50) were
randomly selected from the training set to generate a cumulative
distribution graph depicting the genome-wide distribution of CVs across
tumors (red line) and controls (green line). Genes to the left of the
distribution curve correspond to genes with decreased CV (stably
expressed), while genes on the right are associated with increased CV.
The threshold CVT of 0.28 (black dotted line) represents the CV value
where ,16% of genes in tumor samples are considered to be tightly
regulated (i.e., CV,CVT, see Main Text for details). B) Expression variation
of individual PGC genes in tumors and non-malignant samples. The
height of the bar chart represents each gene’s mean expression level (in
log scale) across all tumor and normal samples in the training set. Error
bars (red lines) represent 2 standard deviations of expression values. PGC
genesshowsignificantlyrestrictedvariationintumors(bluebar)relatedto
control (yellow bar). P-values calculated by F-test were provided for each
PGC gene (x-axis). Note that the mean expression levels of the PGC genes
are similar between tumors and controls.
doi:10.1371/journal.pgen.1000129.g001
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data (gliomas, gastric, NPC, and ovarian), II) one data set
(Yu_Gastric&NPC) representing a mix of two different tissues, and
III) a collection of cancer cell lines (NCI60) from nine different
tissues. A summary of these nine data sets can be found in Table
S2 and the corresponding references. Using a similar strategy to
the RSS test sets, a significant fraction of the PGC genes were
tightly regulated in all nine primary tumor data sets (p-value range:
0–0.002) (Table 1A), confirming the existence of the PGC in a
wide variety of solid tumors. In total, 19 out of 48 PGC genes
repeatedly exhibited reduced expression variation in more than
half of the 9 cancer test sets (Table S3). We also performed the
reciprocal experiment and evaluated the regulation of the PGC in
a series of independent non-malignant samples. Although such
datasets are rarer in their availability and typically smaller than
cancer datasets, we collected two distinct cohorts comprising 115
normal tissues from various organs [33,34]. Notably, these non-
malignant samples were obtained from healthy donors, and are
thus free of malignancy and representative of true normal samples.
In stark contrast to the cancer data sets, the PGC genes exhibited
either no or only a marginal degree of tight regulation in the
normal data sets (p=0.07 and 0.01; Table 1B). Thus, these results
indicate that the precise regulation of the PGC genes is largely
restricted to cancer tissues, suggesting that diverse tumor types
may harbor a general requirement for tightly regulating PGC
expression.
PGC Genes Are Associated with Multiple Cancer Related
Pathways
A pathway analysis revealed multiple highly significant
interactions between the PGC genes and prevalent tumorigenic
pathways. The top-scoring molecular network for the PGC
comprised 11 PGC focus genes interacting either directly or
indirectly with the well-known cancer-related transcription factors
Myc and TP53 (p=10
219, see Methods) (Figure S1), and the most
significantly enriched cellular functions in the PGC were cancer
Figure 2. Identification and Cross-validation of the PGC. A) CV of PGC genes in RMA-processed data. Y-axis is the ratio for CV(tumor)/
CV(control). Each bar represents a PGC gene. Red bars represent PGC genes with ratio less than 1, indicating the expression variation in tumors is
smaller than in controls. Blue bars represent PGC genes with ratio greater than 1. B) Distribution of absolute expression levels for individual PGC
genes. For each gene, the X-axis represents its expression level in tumors and the Y-axis its expression in non-malignant tissues. The PGC genes (black
spots) located around the diagonal line (i.e., expression ratio of control/tumor=1) are randomly scattered across the whole 5729-gene set (gray
spots). C) and D) Repeated Random Sampling (RRS) to assess PGC robustness. C) Genes belonging to the original PGC signature (blue lines) that were
re-identified in at least 500 of 1,000 re-sampled RRS PGC signatures. The red bar represents the only gene (KHDRBS1) not belonging to the original
PGC signature that was re-selected to the same frequency (i.e. .50%). D) Robustness of re-selected PGC signatures in 1,000 cross-validation test sets.
The PGC gene set was queried against either the set of tumor (blue line) or non-malignant tissues (red line) in the cognate RRS cross-validation test
set. PGCRT in the figure indicates the PGCRTumortest comparison. The Y-axis represents the statistical significance of overlap between any re-
selected PGC signature and the cohort of tightly regulated genes in the tumor and non-malignant test sets (assessed by the hypergeometric
distribution, with p-values of p,0.01 (dotted line) being deemed significant).
doi:10.1371/journal.pgen.1000129.g002
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(p,0.0045). The PGC was also significantly enriched in
components related to integrin signaling (p=2.33E
204; Figure S1),
a complex signaling pathway implicated in both positive and
negative regulation of tumor cell growth and cancer metastasis.
Besides integrin signaling, other individual PGC genes, such as RPS2
and RPL7A, have also been previously implicated in the control of
cellular transformation, tumor growth, aggressiveness, and metasta-
sis [35,36]; while the PGC gene MUS81 has recently been reported
to interact with p53 to maintain genome stability [37]. Thus, an
array of biological and functional evidences suggest that the PGC
genes are likely to be involved in the activity of multiple cancer-
related pathways, and not ubiquitous ‘housekeeping’ cellular
functions. The full list of PGC genes is provided in Table S3.
Subtle Alterations in PGC Expression Are Associated with
Metastatic Capacity of Cancer Cells
The tightness of PGC regulation in tumors might be explained if
small alterations in the expression levels of these components are
sufficient to cause significant phenotypic changes in tumors. We
employed three experimental assays to address this possibility.
First, we analyzed a set of colon cancer cell lines derived from
either primary tumors or distant metastases from the same patient
(SW480 and SW620), which have been shown to exhibit several
phenotypic differences including metastatic potential [38,39].
Using Gene Set Enrichment Analysis (GSEA, [40]), we found
that PGC expression was subtly yet significantly decreased in
highly metastatic SW620 cells compared to poorly metastatic
SW480 cells (p,0.001, Table S4). Second, we then analyzed
patterns of PGC expression in a cohort of 30 breast cancer cell
lines, where the invasive capacity of each line had been previously
measured by matrigel assays [32]. The PGC genes exhibited
minimal expression variation across the lines when assessed using a
standard range of expression variation, consistent with their being
tightly regulated in cancers (Figure 3A, left heat-map). However,
when the scale of variation was amplified, we identified by
hierarchical clustering two groups of cell lines showing either
subtly higher or lower levels of PGC expression (Figure 3A, right
heat-map). Importantly, we again found that the majority of cell
lines with high to moderate invasive abilities exhibited subtle yet
significant decreased expression of the PGC genes compared to
poorly invasive lines (p=0.04, chi-square test, sample groups
defined on the basis of the top-level branch point). To validate the
robustness of this clustering by an alternative method, we then also
performed independent k-means clustering (k=2). Using k-means,
7 out of 8 highly invasive cell lines were clustered into one group
together with 4 marginally or non-invasive cell lines (p=0.01, chi-
square test for high vs. marginal/non-invasive), consistent with
the groupings observed by hierarchical clustering. Third, we
conducted in vivo experiments using a murine xenograft model
of metastasis, where poorly metastatic HCT116 colon cancer
cells were injected into the spleens of nude mice, and metastatic
liver tumor nodules were harvested 6 to 8 weeks later. The liver
nodules were expanded in culture and re-passaged in mice to
generate a panel of lines (M1, M2, and M3) with increasing levels
of metastatic capacity (Figure 3B). Examining the gene expression
profiles of these lines, we found that highly metastatic cells
once again exhibited subtly decreased PGC expression compared
to poorly metastatic HCT116 cells (p=0.03, Figure 3B and
Table S4). These results, based on three different experimental
models of metastasis, collectively suggest that small alterations in
PGC expression in tumors may be associated with potent
differences in tumor physiology, specifically metastatic and
invasive capacity.
Functional Silencing of Multiple PGC Genes Enhance
Cellular Invasion
To directly demonstrate the functional role of PGC genes in
cellular invasion, we performed siRNA experiments where five
PGC genes (p53CSV, MAP3K11, MTCH2, CPSF6, SKIP) were
silenced in poorly-metastatic AGS gastric cancer cells. While
p53CSV is a gene required for p53-mediated cell survival [41], its
role in cancer is otherwise poorly understood. Furthermore,
associations between MAP3K11, MTCH2 and CPSF6 to cancer
have also not been previously reported. The siRNA treatments
reduced the expression levels of these five PGC genes from 45%–
80%, as assessed by quantitative real-time PCR (Figure 4A), and
reductions in p53CSV, MAP3K11, MTCH2 and CPSF6 resulted in
a significant enhancement of in vitro invasive activity as measured
in a matrigel assay (p,0.01, one-tailed t-test, Figures 4B and 4C).
Furthermore, SKIP siRNA treatment resulted in a significant
inhibition of cellular proliferation in AGS cells (p,0.01,
Figure 4D). It is worth noting that for at least two genes
(p53CSV and CPSF6), a partial reduction of gene expression of 45–
60% was able to trigger a significant change in invasive phenotype.
To further demonstrate the generality of this phenomenon, we
then knocked down p53CSV in another poorly-metastatic colon
cancer cell line, HCT116 which we previously utilized in the
xenograft assay. Again, the partial silencing of p53CSV expression
significantly increased the invasion activity of HCT116 cells
Table 1. Validation of the PGC in Independent Data Sets.
Table 1A (Cancer) Yu_Gastric&NPC (99
e) Wang_Breast (286) Sotiriou_Breast (189) Bild_Ovarian (125) Bild_Lung (118)
PGC 48
a 28
b/658
c 0
d 24/539 0 27/742 5E-12 21/488 9E-11 13/348 3E-06
Phillips_Glioma (77) Aronow_Colon (100) NCI-60 (60) Neve_BCL (51)
PGC 48 20/585 1E-17 27/1125 2E-8 13/293 5E-07 9/410 0.002
Table 1B (Normal) Symatlas (158) (79 Tissues) Ge (36) (36 Tissues)
PGC 48 6/345 0.07 10/542 0.01
aNumber of genes in the original PGC signatures (e.g., PGC=48 genes).
bNumber of PGC signature genes that are tightly regulated in the test sets (CV,0.28).
cTotal number of tightly regulated genes in the test sets (CV,0.28).
dStatistical significance of PGC signature enrichment, calculated by the hypergeometric distribution test. P-values with significance (,0.01) are highlighted in bold.
eNumber of samples in the test data sets.
doi:10.1371/journal.pgen.1000129.t001
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roles in regulating cancer invasion and metastasis.
Subtle Alterations in PGC Expression Are Associated with
Clinical Outcome
To extend the potential role of precise PGC regulation to the
clinical context, we asked if similar small changes in PGC
expression might be associated with significant differences in
patient survival and clinical outcome. We employed hierarchical
clustering to group the tumors in each of the six data sets with
survival data available by their overall level of PGC expression. A
representative example is shown in Figure 5A. Once again, the
PGC genes exhibited minimal expression variation across the
tumors when assessed on a standard scale of expression variation,
consistent with their being tightly regulated in tumors (Figure 5A,
left heat-map). However, when the variation scale was amplified,
we identified two groups of tumors showing either subtly higher or
lower levels of PGC expression (Figure 5A, right heat-map).
Remarkably, a Kaplan-Meier survival analysis revealed that in all
six data sets, patients with tumors expressing PGC levels below the
population average experienced significantly worse survival
outcomes compared to patients with high-PGC expressing tumors
(Figure 5B; all cases p,0.05 except in ovarian cancer set where
p=0.057, see Figure S4 for clustering groupings). We only
observed comparable survival stratifications across the six data
sets in 46 out of 10,000 randomly selected 48-member gene sets,
arguing that the prognostic ability of the PGC is statistically unique.
In a multivariate analysis, PGC expression behaved as an
independent prognostic factor compared to other clinical variables
in the breast and colon cancer cohorts, and was associated with
tumor stage in ovarian, lung and glioma cancer patients (Table S5).
Importantly, the PGC exhibits very little overlap with other
expressionsignaturesreportedtopredictclinicalbehaviorinmultiple
tumortypes.AcomparisonofthePGCagainsta128-genemetastasis
signature (MS) [42], a 70-gene chromosomal instability signature
(CIN70) [43], a cell cycle module [44], a wound response healing
signature [45,46], and multiple cell proliferation-related signatures
(57–59) including a 874-gene cell cycle gene signature (CPS) [47],
revealed that there was no direct overlap in gene content between
thePGCandtheseother‘‘multi-tumor’’genesignatures,exceptfora
one-gene overlap with the CIN70, and a four-gene overlap with the
CPS,which wasnot statisticallysignificant.This finding suggests that
the specific gene content of the PGC is distinct from other previously
described signatures. To ask if the PGC might target the same ‘‘poor
prognosis’’ tumors as other published signatures capable of
predicting clinical outcome in multiple tumor types, we then
investigatedtheabilityoftheMS,CIN70,andCPSto stratifypatient
survival in the six data sets - none of these signatures exhibited
comparable prognostic significance to the PGC across the six patient
Figure 3. Subtle Alterations in PGC Expression are associated
with invasion and metastasis in vitro and in vivo. A) Variation in
PGC expression in breast cancer cell lines with differing invasive
capacities. (Left) Expression heat-map depicting the range of PGC
expression under a normal scale of variation, based on the top 900
varying genes in the data set (26 to 6.6 fold, top scale bar). Under this
normal scale, the PGC genes (blue column) are near black and show
minimal expression variation across the cell lines. (Right) Expression
heat-map depicting the range of PGC expression under a magnified
scale of variation (21.7 to 0.78 fold, compare purple bars between the
left and right heat-maps). This heat-map represents the predominant
pattern of gene expression, and does not contain 13 outlier PGC genes
(see Figure S2). It worth noting that unsupervised hierarchical clustering
based on the entire 48 PGC gene set was used to segregate the cell
lines. Chi-square tests comparing the numbers of lines with no
metastatic capacities in the two groups were assessed using the top
level branch in the clustering tree (red arrows). Invasive capacities of the
cell lines (none, high, marginal) were derived from Neve et al., 2006. B)
Xenograft model of metastasis. Bar chart depicting the increasing
metastatic potential of M1 to M3 cell lines compared to parental HCT116
cells. The x-axis depicts the number of metastatic modules observed per
mouse, while the y-axis depicts the number of mice used in each
experiment (n=5 to 7 mice per cell line). C) Expression heat map showing
expression of the PGC signature in HCT116, M1, M2, and M3 cell lines,
aligned fromtoptobottom. Three independentbiologicalreplicateswere
profiled for each cell line. Red, black and green squares indicate high,
moderate, and low expression respectively. Individual PGC gene names
are listedbelow the heat-map. Notethat the range ofexpression variation
across the lines is very small, as shown by the scale-bar (20.8 to 0.8 fold).
This heat-map represents the predominant pattern of gene expression,
and does not contain 8 outlier PGC genes (see Figure S2). Once again, the
unsupervised hierarchical clustering based on the entire 48 PGC gene set
was used to segregate the cell lines.
doi:10.1371/journal.pgen.1000129.g003
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likely to target different molecular features and types of tumors than
the aforementioned signatures.
Conventional Microarray Analysis Methods Fail to Detect
the Majority of the PGC
Previous gene expression studies comparing tumors and non-
malignant tissues have typically employed microarray analysis
algorithms such as t-tests with false positive correction or SAM
[20]. Genes detected by such techniques typically require both
differing mean expression levels and equivalent levels of variation
between two cellular states (Figure S5). However, the PGC might
not be detected by such conventional techniques, as PGC genes
might not exhibit distinct mean expression levels between the two
groups and only be associated with differing degrees of expression
variation between tumors and controls (Figure S5). Indeed,
performing SAM and t-tests on the training set only identified
27% of the original PGC, after multiple hypothesis correction, and
the absolute mean expression levels of many PGC genes between
tumors or non-malignant tissues were highly similar (Figure S5).
To ask if the unequal distributions in expression variation might
underlie the failure of the PGC genes to be identified by
conventional techniques, we also analyzed the original training
data set using Welch’s test, an adaptation of Student’s t-test
intended for use with two groups having unequal variance. Again,
75% of the PGC genes failed to be detected as significant using
Welch’s test (data not shown). These findings suggest that
conventional algorithms would likely have failed to detect the
PGC, thereby providing a partial explanation as to why the PGC
might have been missed in previous studies.
Discussion
In this study, we identified a novel cassette of genes exhibiting
tumor-specific precise regulation in multiple cancer tissues. Our
ability to discern the PGC was facilitated by the use of an analysis
method focused on expression variance rather than expression
levels. The reduced variance of the PGC in tumors is unlikely to be
a technical artifact of the Affymetrix platform, as it was not related
to probe selection, data normalization, absolute high or low
expression levels in either tumors or non-malignant tissues, or
sample set. Using both rigorous cross-validation (RSS) and
multiple independent validations, we found the PGC to be robust
to alterations in training set composition and repeatedly observed
in diverse malignant tumor types, including several tissue types not
present in the original training data. Importantly, the PGC failed
to demonstrate tight regulation in several non-malignant tissue
data sets, arguing that its control is cancer-specific. Interestingly,
even though it was not a specific requirement in our initial
analysis, the majority of PGC genes exhibited similar mean
expression levels in both tumors and non-malignant tissues. This
absence of a distinct difference in mean expression values resulted
in the failure of standard microarray analysis methods (e.g., t-test)
to detect the majority of PGC genes when applied to the same
training data set. Furthermore, a standard practice in microarray
data processing is to filter out genes exhibiting low variation prior
to clustering or statistical analysis - such filtering would inevitably
lead to a bias towards differentially expressed genes and prevent
the discovery of the PGC.
One potential concern might be that the PGC genes simply
reflect the activity of tissue-specific gene expression. However, five
findings argue against this possibility. First, while dedifferentiated
Figure 4. Reducing PGC gene expression by siRNA enhances the invasive behavior of AGS gastric cancer cells. A) Real-time PCR
quantification of siRNA mediated knockdown efficiency of five PGC genes (p53CSV, MAP3K11, MTCH2, CPSF6 and SKIP). The y-axis represents the
percentage of relative silencing achieved by the different siRNA treatments. Relative silencing was calculated by comparing PGC gene expression
levels between cells treated with either control or PGC target siRNAs. For each siRNA treatment, the expression levels of the PGC genes were
normalized against the GADPH expression level. B) Representative photographs of AGS cells in the matrigel invasion assay. The left panel depicts
control siRNA treated cells, while the right panel indicates p53CSV siRNA treated cells. Note the increased number of invading cells in the right panel.
C) Summary graph of invasion effects caused by PGC gene silencing. Significant enhancements in cellular invasion were observed for p53CSV,
MAP3K11, MTCH2, CPSF6 (* symbols, P,0.01). P-values were calculated using a one-tailed t-test. D) Summary graph of cell proliferation effects caused
by PGC gene silencing. Significant reductions in cell proliferation were only observed for the SKIP siRNA treatments. P-values were calculated using a
one-tailed t-test.
doi:10.1371/journal.pgen.1000129.g004
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expression (Rhodes et al. 2004); such a loss would typically result
in tissue-specific genes being down-regulated in their absolute
expression levels compared to normal tissues. In contrast, the PGC
genes do not exhibit significant differences in their absolute
expression levels between cancers and normal tissues (Figure 2B).
Second, the reduced variation of the PGC genes was consistently
observed in multiple independent sets from diverse tissues (e.g.
gliomas, lung, breast), including a data set (NCC) that combined
tissues from two different sources (gastric and NPC tumors). Third,
the PGC genes also showed reduced expression variation in the
NCI60 test set - a mixture of cancer cell lines from 9 different
tissue types. Fourth, the PGC genes consistently exhibited reduced
expression variation in the repeated random sampling (RSS) cross-
validation assay, where we tested 1000 distinct training set and
independent test sets composed of mixed tissue types (Figure 2D).
Fifth, even within each of the six tissue types in the training set
(liver, colon, esophagus, thyroid, lung, and breast), the majority of
the PGC genes (70%) are not differentially expressed within
tumors and normals (p.0.01, t-test) (YK, data not shown). Taken
collectively, it is unlikely that the consistency of the PGC would
have been observed if its reduced expression variation was solely
due to tissue-specific expression, supporting the notion that the
PGC genes are likely to be distinct from the conventional
differentially expressed gene signatures described in most micro-
array studies.
One possible explanation for why certain genes may require
precise control is if they regulate or are involved in balancing
disparate downstream pathways possessing mutually opposing
activities. In cancers, the successful establishment of a malignant
tumor involves multiple pro- and anti-oncogenic forces involved in
cellproliferation,apoptosis,celldeath,senescence,celladhesion,and
motility, all of which require delicate balance by different genetic
components. For example, while loss of Ras signaling is lethal,
aberrant signaling through this pathway is important for cancer
development but can also drive cells into either senescence or cell
proliferation, depending on cellular context [48,49]. Another good
example is the anti-apoptotic gene Akt/PKB (protein kinase B),
which when constitutively activated reduced metastases in mice and
inhibited the invasion of breast cancer cells [50,51], indicating its
involvement in multiple cancer pathways. Reassuringly, similar
examplesofbalancedcoordinatorgenesarealsoseeninthecohortof
PGC genes. The PGC gene FUS1 (also known as FUS)h a sb e e n
reported as a tumor suppressor gene in lung and breast cancer [52]
and a pro-oncogene in leukemia [53]. Oxidative stress, which may
play an important role in cancer progression and the regulation of
cancer metastasis [54], is dependent upon the critical balance
between intracellular hydrogen peroxide H2O2 and superoxide
O2
2. Two PGC genes - p53CSV and KIAA0247 have been reported
to be induced in response to oxidative stress [55], and may influence
this balance and the response of tumor cells to apoptotic stimuli [56].
It is also worth noting that the PGC was significantly overrepre-
Figure 5. PGC Expression in Primary Tumors Predicts Clinical Outcome. A) Variation in PGC expression in primary breast tumors. (Left)
Expression heat-map depicting the range of PGC expression under a normal scale of variation, as assessed by the top 900 varying genes in the
Wang_Breast data set (211 to 7 fold, top scale bar). Under this normal scale, the PGC genes (blue row) are near black and show minimal expression
variation across the tumors. (Right) Expression heat-map depicting the range of PGC expression under a magnified scale of variation (20.39 to 0.35
fold, compare orange bars between the left and right heat-maps). Unsupervised hierarchical clustering was used to segregate the tumors. All
subsequent Kaplan-Meier analyses were performed between groups defined by the top level tree branch (purple and green samples). B)–E) Kaplan-
Meier survival analysis of patient groups stratified by the PGC expression in primary tumors. Significantly distinct survival outcomes were observed in
patients whose tumors express increased PGC levels compared to low-PGC expression patients, in the B) Wang_Breast set (p=0.015), C)
Sotiriou_Breast (p=0.003), D) Bild_Lung (p=0.014), and E) Bild_Ovarian cancer cohorts (p=0.057), F) Phillips_Glioma cancer (p,0.001), and G)
Aronow_Colon cancer cohorts (p=0.005). The outcome metric was relapse-free survival for B), C), and G) and overall survival for D), E) and F).
doi:10.1371/journal.pgen.1000129.g005
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complex process involving multiple related family members with
roles in many cellular functions, including ERK/MAPK and JNK/
SAPK regulated gene expression, cell motility, cytoskeletal interac-
tions, and PI3K and Wnt pathway signaling [57]. In metastasis,
integrins are crucial for cell invasion and migration, not only for
physically tethering cells to the matrix, but also for sending and
receiving molecular signals regulating these processes [57]. More-
over, while some groups have proposed that increased integrin
expression could promote malignant behavior by enhancing tissue
stiffness [58], other groups have suggested that loss of integrins may
promote tumor invasion and metastasis [59]. The complexity of
integrin family members and their pathway components also
provides a plausible explanation for why even subtle alterations in
PGC expression are associated with distinctand measurable changes
in metastatic behaviour in both experimental models of metastasis
and clinical outcome.
What might be the mechanistic basis of precise PGC regulation?
At a general level, many precisely-regulated genes are likely to
possess complex regulatory systems for tightly controlling expres-
sion levels, to rapidly sense and adapt to dynamic perturbations in
both the internal and external environment [60]. Such mecha-
nisms could involve the use of both positive and negative feedback
loops, analogous to the circuitry utilized by the LacI/O bacterial
system to ensure precise expression [61], but in cancers could also
involve eukaryote-specific mechanisms like epigenetic modifica-
tions (DNA methylation or chromatin modifications), microRNA
regulation, or transcription factor binding. Interestingly, in a
preliminary analysis, we attempted to extend our observations
from the pathway analysis showing an association of several PGC
genes with both Myc and TP53. Specifically, we investigated
whole-genome transcription factor binding data for Myc and TP53
[62], and found that the PGC genes were weakly but significantly
associated with Myc binding sites under Myc-overexpressed
(tumorigenic) conditions (p=0.04) but not under physiological
conditions (p=0.3) (Table S6). These preliminary results raise the
possibility that transcription factor binding, specifically Myc
binding, may constitute one possible mechanism for PGC
regulation in cancer cells. However, deciphering the mechanism
of PGC regulation will undoubtedly require further research.
Cancers have been proposed to possess robustness mechanisms
for protection against various therapeutic perturbations and
naturally occurring microenviromental (e.g., hypoxia) and im-
mune responses. However, many complex systems have evolved to
exhibit a ‘robust yet fragile’ structure [63,64], and it has been
proposed that studying mechanisms of cancer-specific robustness
and accompanying fragilities might prove useful for the develop-
ment of novel targeted therapies [65–67]. The PGC gene cassette
reported here may indicate such fragilities in the network of tumor
cells, as subtle alterations on these components significantly
affected the cellular behavior of cancer cells. Beyond cancer, this
approach is conceptually applicable and easily transportable to
other disease conditions where gene expression data is available. It
will be interesting to explore if the approach will also prove
informative in identifying genes and pathways with important roles
in other human pathophysiologies.
Materials and Methods
Microarray Data Sets
The training data set contained 270 primary human tumors
(Lung=18, Thyroid=35, Liver=9, Esophagus=16, Colon=9,
Breast=183) and 71 adjacent non-malignant tissues (Lung=12,
Thyroid=16, Liver=8, Esophagus=13, Colon=9, Breast=13)
obtained from the Tissue Repository of the National Cancer
Centre of Singapore (NCCS). The phrase ‘non-malignant’ instead
of ‘normal’ was used to describe the control tissues in the training
set, as they were also obtained from cancer patients. Institutional
approvals were obtained from the NCCS Tissue Repository and
Ethics Committees. Descriptions of sample collection protocols,
archiving, and histological assessments are presented in the Text
S1. RNA was extracted from the tissues using Trizol reagent
(Invitrogen, Carlsbad, CA) and processed for microarray hybrid-
izations on Affymetrix U133A Genechips according to the
manufacturer’s instructions (Affymetrix Inc., Santa Clara, CA).
The expression data has been deposited into the Gene Expression
Omnibus (GEO) database (GSE5364).
Data Preprocessing
Raw Genechip scans were processed using either the MAS5
algorithm (Affymetrix) normalized by median-centering (Gene-
Data, Basel, Switzerland), or by robust multiple chip analysis
(RMA) [24,25] (see Results). To identify reliably measured genes,
we discarded probes with ,80% present values (P-call ,80%)
across the training set samples. For genes with multiple probes, we
selected the best-match probes (to targets) represented by a ‘‘_at’’
extension. For genes with multiple ‘‘_at’’ extension probes, the
probe with the highest P-call rate (i.e., the highest valid value
proportion) was used. The final pre-processed training set
comprises 5729 unique genes, each represented by a single probe.
Coefficient of Variance (CV)
Gene expression CVs (standard deviation divided by the mean
expression level) were used to compute the variability of expression
for each gene. Based on the global distribution of CVs in the
training set, we selected an empirical threshold of CVT=0.28
below which a gene was considered to be tightly regulated (see
Results). Prior to comparing gene CVs between populations, we
also confirmed that the global CV distributions for different
sample cohorts (i.e., tumor or non-malignant) were similar.
Repeated Random Sampling (RRS)
To estimate the probability that the PGC signatures might be
generated by chance, we randomly shuffled the class labels (i.e.,
tumor or non-malignant) of the training set to generate multiple
class-permuted sample sets and determined the frequency a
particular PGC gene could be re-identified in situations where the
sample labels were shuffled. Repeated Random Sampling (RRS), a
rigorous cross-validation strategy described in [27], was also used
to determine the influence of particular training set compositions
on selecting specific signature genes. Detailed descriptions of the
class permutation and RSS tests are provided in the Text S1.
Validation of the PGC in Test Sets
The hypergeometric distribution was used to test if the PGC
genes were significantly over represented in the population of
tightly controlled genes in each test set. First, we identified genes
exhibiting tightly controlled expression in the test set, using the
CVT threshold cut-off (CV(Test),CVT). Second, we determined
the overlap between the PGC gene signatures and the population
of tightly regulated genes in the test set, and the hypergeometric
distribution test was used to calculate the significance of the
overlap. Significance was defined as p,0.01.
Pathway Analysis
We used Ingenuity Pathway Analysis (IPA, Ingenuity Systems)
to identify molecular networks, cellular functions, and signaling
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displayed as nodes (genes) and edges (biological relationships
between genes). We also used IPA to identify cellular functions and
signaling pathways that were significantly enriched in the PGC.
The significance of a pathway association is reflected by a Fisher’s
exact test p-value, indicating the likelihood that the pathway would
have been identified by random chance.
Invasion and Proliferation Assays
AGS gastric cancer cells and HCT116 colon cancer cells were
cultured according to American Type Culture Collection (ATCC)
recommendations. Cells were transfected with either siRNA pools
of representative PGC genes p53CSV, MAP3K11, MTCH2, CPSF6
and SKIP (Dharmacon, Lafayette, CO) or non-targeting siRNA
controls at 100 nM concentration, using oligofectamine reagent
(Invitrogen) at 0 and 24 hr time points, in 6 well culture plates.
Gene silencing was verified by Real time PCR. Invasion assays
were performed using Biocoat matrigel invasion chambers (BD
Biosciences, Bedford, MA) as recommended by the manufacturer.
48 hrs after siRNA transfection, equal numbers of target gene
siRNA transfected cells and non-targeting siRNA transfected cells
were placed in the invasion chambers, and after 24 hrs cells that
successfully invaded through the matrigel invasion chambers were
scored. Each experiment was repeated thrice and the percentage
of invasion was calculated by comparing against the non-targeting
siRNA transfected cells. To assay cell proliferation, AGS cells
transfected with the PGC genes and non-targeting control siRNA
in 6 well culture plates were harvested at 96 hrs after siRNA
transfection and counted. Experiments were performed thrice.
Quantitative Real-time PCR
Total RNA was reverse transcribed using Taqman Reverse
Transcription Reagent kit (Applied Biosystems, Foster City, CA)
and quantitative PCR was performed using the following Taqman
probes: p53CSV (Hs00429934_g1); MAP3K11 (Hs00176759_m1);
MTCH2 (Hs00819318_g1); CPSF6 (Hs00199668_m1); SKIP
(Hs00273351_m1), on a 7900HT Fast Real time system (Applied
Biosystems, Foster City, CA). Taqman GAPDH probes (glyceral-
dehyde phosphate dehydrogenase) (Hs99999905_m1) were used as
internal controls. All samples were run in triplicates.
Experimental Systems of Cancer Metastasis and Invasion
(A) Colorectal cancer model : this comprises two colon cancer
cell lines derived from either primary or distant metastases from
the same patient (SW480 and SW620). SW480 and SW620 cells
exhibit several phenotypic differences including metastatic poten-
tial [38,39]. Gene Set Enrichment Analysis (GSEA) was performed
as described in [40]. (B) Breast cancer panel: this comprises a panel
of 51 breast cancer cell lines for which gene expression data is
available [32], and where the relative invasive capability of 30 lines
has been measured using matrigel assays [32]. (C) Murine assay:
this comprises an in vivo passage model where poorly metastatic
HCT116 colon cancer cells were injected into mouse spleens, and
subsequent hepatic metastases were harvested to generate
increasingly metastatic cellular variants. Details of this model are
provided in the Text S1. The animal work performed was
approved by the National University of Singapore Institutional
Animal Care and Use Committee (NUS IACUC). Cells obtained
from the hepatic metastatic nodules after the first passage were
named M1, and the selection procedure was repeated twice to
obtain the M2 and M3 cell lines. Three independent replicates
were profiled for each cell line.
Clinical Outcome in Primary Patient Cohorts
Hierarchical clustering (average linkage metric with Pearson
correlation) was used to cluster tumors into different groups on the
basis of their PGC expression levels. Kaplan-Meier analysis
(SPPC, Chicago) was used for survival comparisons between the
tumor groups. P-values were calculated using the Log-rank test.
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